News
News Item
New Strategy for Avoiding Waste and Improving Response for Highest Cost Therapies in Rheumatoid Arthritis
AMCP Science & Innovation Theater Webinar Speakers: James T. Kenney, MBA, RPh, President, JTKENNEY, LLC Alif Saleh, CEO, Scipher Medicine...
News Item
Scipher Medicine Announces Publication of Clinical Study Validating PrismRA, a Blood Test Predicting Non-Response to TNF Inhibitor Therapies in Patients with Rheumatoid Arthritis
PrismRA identifies patients 6.6 times less likely to respond to TNFi therapy JULY 28, 2020- WALTHAM, MA- (Business Wire)- Scipher Medicine,...
News Item
Clinical validation of a blood-based predictive test for stratification of response to tumor necrosis factor inhibitor therapies in rheumatoid arthritis patients
Abstract Objectives: For rheumatoid arthritis (RA) patients failing to achieve treatment targets with conventional synthetic disease-modifying antirheumatic drugs, tumor necrosis factor...